3 Reasons to Buy Novo Nordisk Stock Right Now

Novo Nordisk, despite a 40% stock decline over the past year, presents strong future growth potential driven by key regulatory advancements and a robust pipeline in the lucrative GLP-1 market. Recent approvals include Wegovy for MASH in the U.S. and Rybelsus for cardiovascular risk reduction in Europe, while its pipeline features an oral semaglutide for weight management and the innovative triple-hormone mimetic UBT251. Additionally, potential U.S. Medicare coverage for GLP-1 drugs could significantly expand market access, underpinning the company's long-term prospects in metabolic health.

Analysis

Despite a reported 40% stock price decline over the past twelve months, Novo Nordisk exhibits a compelling forward-looking growth profile supported by significant regulatory, pipeline, and market access catalysts. The company recently secured a key U.S. label expansion for Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH), an indication with strong demonstrated demand, evidenced by Madrigal's Rezdiffra generating $350 million in its fiscal 2025. This expansion alone could add over $1 billion in sales for Wegovy. Further regulatory momentum includes a European label expansion for Rybelsus to reduce cardiovascular events, with reciprocal approvals for both drugs anticipated in the U.S. and Europe. The pipeline remains robust, with a U.S. application submitted for a first-to-market oral semaglutide for weight management and preparations for CagriSema, which is estimated to have a sales potential of $15.2 billion by 2030. Strategically, Novo Nordisk is countering competitor Eli Lilly by licensing UBT251, a novel triple-hormone agonist, for $200 million upfront and up to $1.8 billion in milestones. A potential U.S. pilot program for Medicare and Medicaid coverage of GLP-1 therapies could significantly expand the addressable market by overcoming current price barriers, further bolstering the company's long-term outlook.

Key Decisions for Investors

• Given the reported 40% stock price decline against a backdrop of positive regulatory developments and a strong pipeline, investors could consider the current share price an attractive entry point for long-term exposure to the GLP-1 market.
• It is critical to monitor near-term catalysts, including the U.S. decision on Rybelsus for cardiovascular health, the European decision on Wegovy for MASH, and any definitive announcements regarding the U.S. CMS pilot program for anti-obesity drug coverage.
• Investors should track the clinical and regulatory progress of key pipeline assets like oral semaglutide and UBT251, as their success is crucial for Novo Nordisk to maintain its competitive position against rivals such as Eli Lilly.
• Consider the contrast between the article's bullish thesis and the noted exclusion of NVO from the Motley Fool's '10 best stocks' list as a point of caution, suggesting the need for further due diligence on potential unmentioned risks or relative valuation concerns.